GlassScriptPhysician profile
Dietriche Jones
NPI 1376724799
$5,611.88
in general payments reported to CMS, 2019-2025
25 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,182 · 2022: $2,383 · 2023: $557 · 2024: $183 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,047.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $3,262.15 | 2021-2022 | |
| Gilead Sciences, INC. | $386.68 | 2021-2025 | Biktarvy |
| Mayne Pharma Commercial LLC | $342.29 | 2022-2025 | |
| Astellas Pharma US INC | $176.45 | 2023-2025 | Veozah |
| Theratechnologies INC. | $161.11 | 2021-2022 | |
| Abbvie INC. | $157.02 | 2021-2024 | |
| Janssen Biotech, INC. | $151.19 | 2021-2022 | |
| Daiichi Sankyo INC. | $129.57 | 2022-2024 | Injectafer |
| Merck Sharp & Dohme LLC | $97.23 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.83 | 2021-2022 | |
| Hologic Sales and Service, LLC | $80.01 | 2023-2025 | Omni Hysteroscope, Novasure, Acessa Provu System |
| Organon LLC | $73.30 | 2022 | |
| Shield Therapeutics INC | $68.61 | 2023-2024 | Accrufer |
| Janssen Products, LP | $65.99 | 2021 | |
| Lilly USA, LLC | $59.65 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $59.14 | 2022-2025 | Slynd |
| Pfizer INC. | $58.76 | 2021 | |
| Novo Nordisk INC | $53.39 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Ironwood Pharmaceuticals, INC | $23.58 | 2021 | |
| Hikma Pharmaceuticals USA | $18.67 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.05 | 2022 | |
| Abbott Laboratories | $15.88 | 2022 | |
| Becton, Dickinson and Company | $14.93 | 2022 | |
| Millicent US INC | $13.92 | 2025 | Femring, Intrarosa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dietriche Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.